Recent study showed that the administration of sodium-glucose co-transporter 2 (SGLT2) inhibitor Empagliflozin significantly reduced cardiovascular death and hospitalization for heart failure in patients regardless of the presence or absence of diabetes (128). This evidence concerns the gene SLC5A2 and heart failure.